Estela Prada Varela
Ayudante de investigación
Research group
Research line:
Treatment of Pediatric Rabdomiosarcoma
The researcher has a degree in Pharmacy since 2014 from the University of Santiago de Compostela.
In 2015, she obtained a master's degree in Translational Biomedical Research from the Vall d'Hebron Research Institute - Universitat Autònoma de Barcelona.
In 2016 she joined as a predoctoral researcher in the Developmental Tumors laboratory of the Sant Joan de Déu Hospital of Dr. Jaume Mora for the development of new targets and pharmacological opportunities in the treatment of pediatric rhabdomyosarcoma.
In November 2021 she obtained her PhD from the University of Barcelona, with her doctoral thesis "Target therapy in Rhabdomyosarcoma: Discovering new targets and opportunities", supervised by Dr. Jaume Mora (SJD) and Dr. Inmaculada Hernandez (IMIM ).
She currently works as a postdoctoral researcher in the Sarcomas and Histiocytosis group, included in the IRSJD Pediatric Cancer program.
Last Publications
- Alcon C, Martín F, Prada-Varela E, Mora J, Soriano A, Guillén G, Gallego S, Roma J, Samitier J, Villanueva A and Montero J MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment. Cell Death Discovery . 8(1): 172-172.
- Sánchez-Molina S, Figuerola-Bou E, Blanco ME, Sánchez-Jiménez M, Táboas P, Gomez-Gonzalez S, Ballaré C, García-Domínguez DJ, Prada-Varela E, Hontecillas-Prieto L, Carcaboso AM, Tirado ÓM, Hernandez-Muñoz MI, de Álava E, Lavarino C, Di Croce L and Mora J RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis. Science Advances . 6(43): 3058.
- Alcon C, Manzano-Muñoz A, Prada-Varela E, Mora J, Soriano A, Guillén G, Gallego S, Roma J, Samitier J, Villanueva A and Montero J Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance. CELL DEATH & DISEASE . 11(8): 634-634.